Abstract
Acute myelogenous leukemia (AML) represents a heterogeneous group of leukemias. It is a rare disease in children, accounting for approximately 20% of acute leukemia in children and adolescents [10]. In contrast to the major advances in childhood lymphoblastic leukemia (ALL), the progress achieved in childhood AML has been less satisfactory. Approximately 20%–25% of children with AML fail to achieve complete remission and a significant number of children in remission still relapse in spite of postremission treatment with polychemotherapy. Since 1978 the German BFM Group conducted three consecutive studies for the treatment of childhood AML, in which 33 hospitals participated [3, 10, 12]. This report updates the latest results of the first two studies BFM-78 and BFM-83 with special emphasis on the main differences between them.
Supported by the Federal Minister for Research and Technology, Federal Republic of Germany
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bennett JM, Catovsky D, Daniel M-T, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1976) Proposals for the classification of the acute leukaemias. Br J Hematol 33: 451 - 458
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1985) Criteria for diagnosis of acute leukemia of megakaryocyte lineage (M7): a report of the French-American-British Cooperative Group. Ann Intern Med 103: 460–462
Creutzig U, Ritter J, Riehm H, Langermann H-J, Henze G, Kabisch H, Niethammer D, Jürgens H, Stollmann B, Lasson U, Kaufmann U, Löffler H, Schellong G (1985) Improved treatment results in childhood acute myelogenous leukemia: a report of the German cooperative study AML-BFM-78. Blood 65: 298–304
Creutzig U, Ritter J, Schellong G (1989) Acute myelogenous leukemia in childhood: analysis of therapy studies AML-BFM-78 and -83 as basis for future risk adapted treatment strategies. Springer, Berlin Heidelberg New York
Grier HE, Gelber RO, Camitta BM, Delorey MJ, Link MP, Price KN, Leavitt PR, Weinstein HJ (1987) Prognostic factors in childhood acute myelogenous leukemia. J Clin Oncol 5: 1026–1030
Holmes R, Keating MJ, Cork A, Broach Y, Trujillo J, Dalton WT, Jr, McCredie KB, Freireich EJ (1985) A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(pl3q22). Blood 65: 1071–1078
Kaplan E, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Kris MG, Mertelsmann R, Jhanwar S, Chaganti R, Szatrowski TH, Gee TS, Arlin Z, Kempin S, Benedetto P, Clarkson B (1985) Relationship of Auer rods and chromosome findings to outcome in eighty-nine adults with acute nonlymphoblastic leukemia. Leuk Res 8: 1231–1235
Peto T, Pike MC (1986) Conservatism of the approximation T(0–E)2/E in the logrank test for survival data or tumor incidence data. Biometrics 29: 579–584
Ritter J, Creutzig U, Riehm H-J, Schellong G (1984) Acute myelogenous leukemia: current status of therapy in children. Recent Results Cancer Res 93: 204–215
Ritter J, Vormoor J, Creutzig U, Schellong G (1989) Prognostic significance of Auer rods in childhood AML: results of the studies AML- BFM-78 and -83. Med Pediatr Oncol 17:202–209
Schellong G, Creutzig U, Ritter J (1985) Treatment of acute myelogenous leukemia in children. Med Oncol Tumor Pharmacother 2: 17–25
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Ritter, J., Creutzig, U., Schellong, G. (1990). Improved Treatment Results in the Myelocytic Subtypes FAB M1-M4 but not in FAB M5 After Intensification of Induction Therapy: Results of the German Childhood AML Studies BFM-78 and BFM-83. In: Büchner, T., Schellong, G., Hiddemann, W., Ritter, J. (eds) Acute Leukemias II. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 33. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74643-7_35
Download citation
DOI: https://doi.org/10.1007/978-3-642-74643-7_35
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-50984-4
Online ISBN: 978-3-642-74643-7
eBook Packages: Springer Book Archive